How Americans aged 25-35 spend their free time, 1920-2026. A shift toward ever more leisure and solitude. The most underrated change is the loss of time spent “doing nothing” (i.e. introspecting).
https://t.co/FBA2Ck504V
🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression
After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️
We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.
This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).
Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.
The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.
At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):
✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)
Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.
The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.
Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.
Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.
Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.
This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.
The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”
@twc_health@McCulloughFund@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
I built https://t.co/R1jAMUfNTv — a free public database for American citizens who deserve safer communities.
You can track which judges released defendants who then got rearrested, skipped court, or violated their release conditions. All public records. All free.
I started with Orange County FL and will be expanding to all 67 Florida counties and eventually every state in the country. This first batch of info is from 2024 and since public reports are released in March/April for the previous year, data is behind. But I wanted to see if this is plausible. After adding 2024,I'll add 2025 and then figure out how to get real-time-data uploaded.
It's in beta — would love to know what you think 👇
Numbers don't lie, but criminals do.
https://t.co/DfTcJ6XMYn
@bennyjohnson@jockowillink@GrantCardone@LauraLoomer@nickshirleyy@j_fishback
DOGE is using AI to remove half of federal regulations because they are illegal.
They’re targeting 100,000 regulations that collectively cost Americans $3.3 trillion per year.
That’s more than the income tax.
In fact, it’s nearly the GDP of Japan.
Full transparency, I did not know about this section on pages 278-279 of the OBBB that strips states of the right to make laws or regulate AI for 10 years.
I am adamantly OPPOSED to this and it is a violation of state rights and I would have voted NO if I had known this was in there.
We have no idea what AI will be capable of in the next 10 years and giving it free rein and tying states hands is potentially dangerous.
This needs to be stripped out in the Senate.
When the OBBB comes back to the House for approval after Senate changes, I will not vote for it with this in it.
We should be reducing federal power and preserving state power.
Not the other way around.
Especially with rapidly developing AI that even the experts warn they have no idea what it may be capable of.
@MichelleMaxwell Newspaper delivery girl, 11yo 5th grade. Then when I was 15 I worked as ward clerk in the rest home across the street. I don't get these kids!
@NASA Is the 3% chance for 2024 YR4 to hit the LEADING edge of Earth surface in the window, or the TRAILING edge? Seems like the former might result in more damage. Who has enough data to share a 3D animation?
@VigilantFox Off to a promising start! Here's to transparency, true safety data, and a system that removes unsafe products from the market so more people don't have to suffer like @Amothersanthem's multi-stroke vaxx-injured @scarletletterv:
https://t.co/q7gtyX2ZPA
https://t.co/X0staffjrY
Since its inception in 1961, USAID has been the financier of American political telescopic philanthropy. Allowing politicians, mainly on the Left but also the Right, to virtue-signal globally at the taxpayer’s expense while ignoring problems at home.
The term "telescopic philanthropy" originates from Charles Dickens' novel Bleak House, published in 1852-1853. In the book, Dickens uses this term to satirize a particular kind of philanthropy practiced by one of his characters, Mrs. Jellyby.
Mrs. Jellyby is obsessed with a charitable project aimed at improving conditions in Africa, specifically in a fictional place called Borrioboola-Gha, while neglecting her own family and home in London. The term "telescopic philanthropy" thus refers to a form of charity where the giver focuses on distant, often exotic causes, while being oblivious to or neglecting local or immediate problems. Dickens uses this to critique the hypocrisy and misdirected efforts of some philanthropists of his time.
Those few USAID programs that truly support national security should be incorporated into the State Department and the residual abolished. Do your part by voting busybody Mrs. Jellyby politicians out of office in 2026.
@smithhmesteadms@ThrivingTheFut True, Started with 4 in a suburb with limits on backyard chickens. Moved out to an acre in the country. Now have 27. One Olive Egger will swallow a snake whole. We added 6 more just like her this year.
WATCH:
This is an old news broadcast from DECADES AGO.
Listen to how the media outlines @JoeBiden’s immorality, his plagiarism & lack of ethics in this broadcast.
Biden has been making a living lying to the American people his whole life!
He must be removed from office. #Trump2024
@RickPercoco1776@oshea4texas On repealing amendments, I would caution against opening up our constitution to any further change. The minute we open that up, they will coerce delegates to add more changes that we don't want.